Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lydia Loke
Observed names:
Loke, Lydia,
Loke, Lydia Pui Yee,
Lydia Pui Yee Loke
Institution:
Ministry of Health
Observed institution:
Ministry of Health
ORCID:
0000-0002-9681-293X
Observed ORCID:
0000-0002-9681-293X
OpenAlex ID:
A5041424712
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
2020
·
Mohamed Ismail Abdul Aziz
, Ling Eng Tan
, et al.
·
Journal of Medical Economics
·
28
PDF
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
2021
·
Li-Jen Cheng
, Lydia Loke
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
·
15
Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
2020
·
Lydia Loke
, Soo‐Chin Lee
, et al.
·
Cancer Reports
·
11
PDF
Use of surrogate endpoints in health technology assessment: A review of company submissions for cancer drugs in Singapore.
2026
·
Jiamin Ong
, Lydia Loke
, et al.
·
Journal of Clinical Oncology
Cost-effectiveness of ruxolitinib in Singapore for patients with chronic graft-versus-host disease
2025
·
Naren Kumar Surendra
, Jiamin Ong
, et al.
·
Expert Review of Pharmacoeconomics & Outcomes Research
PD118 Company-Led Submissions For Cancer Medicines: The Singapore Experience
2024
·
Jiamin Ong
, Lydia Loke
, et al.
·
International Journal of Technology Assessment in Health Care
PDF
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
2020
·
Aziz, Mohamed Ismail Abdul
, Tan, Ling Eng
, et al.
·
Figshare
Show more works
View as search
Works count:
9
Citation count:
54
H-index:
3
I10-index:
3
Year
Topic
Type